Literature DB >> 20131292

Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutières syndrome.

Georgia Ramantani1, Jürgen Kohlhase, Christoph Hertzberg, A Micheil Innes, Kerstin Engel, Susan Hunger, Wiktor Borozdin, Jean K Mah, Kristina Ungerath, Hartmut Walkenhorst, Hans-Helmut Richardt, Johannes Buckard, Andrea Bevot, Corinna Siegel, Celina von Stülpnagel, Chrysanthy Ikonomidou, Kara Thomas, Virginia Proud, Frank Niemann, Dagmar Wieczorek, Martin Häusler, Pascal Niggemann, Volkan Baltaci, Karsten Conrad, Pierre Lebon, Min Ae Lee-Kirsch.   

Abstract

OBJECTIVE: Aicardi-Goutières syndrome (AGS) is an early-onset encephalopathy resembling congenital viral infection that is characterized by basal ganglia calcifications, loss of white matter, cerebrospinal fluid (CSF) lymphocytosis, and elevated interferon-alpha levels in the CSF. Studies have shown that AGS is an autosomal-recessive disease linked to mutations in 5 genes, encoding the 3'-repair DNA exonuclease 1 (TREX1), the 3 subunits of ribonuclease H2 (RNASEH2A-C), and sterile alpha motif domain and HD domain-containing protein 1 (SAMHD1). In this study we further characterized the phenotypic spectrum of this disease.
METHODS: Clinical and laboratory data were obtained from 26 patients fulfilling the clinical diagnostic criteria for AGS. Genomic DNA was screened for mutations in all 5 AGS genes by direct sequencing, and sera were analyzed for autoantibodies.
RESULTS: In 20 patients with AGS, 20 mutations, 12 of which were novel, were identified in all 5 AGS genes. Clinical and laboratory investigations revealed a high prevalence of features (some not previously described in patients with AGS) that are commonly seen in patients with systemic lupus erythematosus (SLE), such as thrombocytopenia, leukocytopenia, antinuclear antibodies, erythematous lesions, oral ulcers, and arthritis, which were observed in 12 (60%) of 20 patients with AGS. Moreover, the coexistence of AGS and SLE, was for the first time, demonstrated in 2 patients with molecularly proven AGS.
CONCLUSION: These findings expand the phenotypic spectrum of lupus erythematosus in AGS and provide further insight into its disease mechanisms by showing that activation of the innate immune system as a result of inherited defects in nucleic acid metabolism could lead to systemic autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20131292     DOI: 10.1002/art.27367

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  82 in total

1.  The TREX1 exonuclease R114H mutation in Aicardi-Goutières syndrome and lupus reveals dimeric structure requirements for DNA degradation activity.

Authors:  Clinton D Orebaugh; Jason M Fye; Scott Harvey; Thomas Hollis; Fred W Perrino
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort.

Authors:  B Namjou; P H Kothari; J A Kelly; S B Glenn; J O Ojwang; A Adler; M E Alarcón-Riquelme; C J Gallant; S A Boackle; L A Criswell; R P Kimberly; E Brown; J Edberg; A M Stevens; C O Jacob; B P Tsao; G S Gilkeson; D L Kamen; J T Merrill; M Petri; R R Goldman; L M Vila; J-M Anaya; T B Niewold; J Martin; B A Pons-Estel; J M Sabio; J L Callejas; T J Vyse; S-C Bae; F W Perrino; B I Freedman; R H Scofield; K L Moser; P M Gaffney; J A James; C D Langefeld; K M Kaufman; J B Harley; J P Atkinson
Journal:  Genes Immun       Date:  2011-01-27       Impact factor: 2.676

3.  Reconciling neuroimaging and clinical findings in Aicardi-Goutières syndrome: an autoimmune-mediated encephalopathy.

Authors:  G Ramantani; P Niggemann; T Bast; M A Lee-Kirsch
Journal:  AJNR Am J Neuroradiol       Date:  2010-06-25       Impact factor: 3.825

Review 4.  [Type I interferonopathies. Systemic inflammatory diseases triggered by type I interferons].

Authors:  C Günther; F Schmidt; N König; M A Lee-Kirsch
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

Review 5.  Neutrophilic dermatoses and autoinflammatory diseases with skin involvement--innate immune disorders.

Authors:  Alexander A Navarini; Takashi K Satoh; Lars E French
Journal:  Semin Immunopathol       Date:  2015-11-30       Impact factor: 9.623

Review 6.  RNase H2-RED carpets the path to eukaryotic RNase H2 functions.

Authors:  Susana M Cerritelli; Robert J Crouch
Journal:  DNA Repair (Amst)       Date:  2019-10-23

7.  Deregulated type I IFN response in TREX1-associated familial chilblain lupus.

Authors:  Katrin Peschke; Franziska Friebe; Nick Zimmermann; Tom Wahlicht; Tina Schumann; Martin Achleitner; Nicole Berndt; Hella Luksch; Rayk Behrendt; Min Ae Lee-Kirsch; Axel Roers; Claudia Günther
Journal:  J Invest Dermatol       Date:  2013-11-22       Impact factor: 8.551

Review 8.  [Familial chilblain lupus : Type 1 interferonopathy with model character].

Authors:  C Fiehn
Journal:  Z Rheumatol       Date:  2017-05       Impact factor: 1.372

Review 9.  Recent insights into the genetic basis of systemic lupus erythematosus.

Authors:  Ornella Josephine Rullo; Betty P Tsao
Journal:  Ann Rheum Dis       Date:  2012-12-19       Impact factor: 19.103

Review 10.  cAMP responsive element modulator: a critical regulator of cytokine production.

Authors:  Thomas Rauen; Christian M Hedrich; Klaus Tenbrock; George C Tsokos
Journal:  Trends Mol Med       Date:  2013-03-13       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.